| Current Evidence for Antithrombotic Therapy after Peripheral Vascular Interventions. | |
| | |
MedLine Citation:
|
PMID: 22272907 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
There is occurring a progressive increase in peripheral arterial disease (PAD) in the United States and around the World. This is undoubtedly associated with deterioration in health status and an increase in cardiovascular risk factors. There are multiple old and new antithrombotic and anticoagulation medications that have been used for the treatment of PAD. Several are considered in this review. The purpose of antithrombotics in surgery is the prevention of thrombosis of surgical bypass grafts in order to help maintain their patency. Multiple different medication approaches can be made in association with surgery. Just as in the case of peripheral vascular surgery, thrombosis also plagues the long-term maintenance of patency following peripheral vascular interventions (PVIs). Platelets play a key role in the initiation and propagation of thrombus formation following these PVIs and the use of antithrombotic medication helps reduce the likelihood of intravascular thrombus formation and adverse ischemic events during and after the procedure. Currently used antithrombotic agents after percutaneous peripheral revascularization include aspirin, clopidogrel, cilostazol and warfarin. Available medications remain in a state of flux and new oral direct thrombin and Factor Xa inhibitors may also find a place as clinical evidence-based medicine accumulates. |
| | |
Authors:
|
Sibu P Saha; Thomas F Whayne; Debabrata Mukherjee |
Related Documents
:
|
7299337 - Consistency of data collected from inmates of a common lodging house. 1377247 - Surgery in collective protection against chemical warfare. 6990737 - Throat cultures in the office. 20825337 - The medical reserve corps as part of the federal medical and public health response in ... 7425157 - "medical responsibility" in institutional settings. 10534087 - Adrenal insufficiency: an uncommon cause of fatigue. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-1-20 |
Journal Detail:
|
Title: Current vascular pharmacology Volume: - ISSN: 1875-6212 ISO Abbreviation: - Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2012-1-25 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101157208 Medline TA: Curr Vasc Pharmacol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Division of Cardiothoracic Surgery, Gill Heart Institute, University of Kentucky, 326 Wethington Building, 900 South Limestone Street, Lexington, KY 40536-0200, USA. twhayn0@uky.edu. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The Effects of Incretins on Energy Homeostasis: Physiology and Implications for the Treatment of Typ...
Next Document: Interactions between Inflammation and Coagulation in Autoimmune and Immune-Mediated Skin Diseases.